JGHG yields 72.46% · PFE yields 6.13%● Live data
📍 JGHG pulled ahead of the other in Year 1
Combined, JGHG + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JGHG + PFE for your $10,000?
Jinzisheng Holding Group, a development stage company, develops and sells enterprise mobile marketing applications solutions, kiosk hardware, and software products. Its solutions include m2Meet, a community networking software solution; m2Bank, a financial transactions system that facilitates bill payments, money transfers, and account management; and m2Market, a mobile marketing solution that is used to deliver marketing materials to mobile phones. The company also offers m2Ticket, a mobile ticketing sales engine, which manages the sale and delivery of tickets through mobile phones for the transportation and entertainment industry; m2Kiosk, a line of standard and custom kiosks hardware and software that integrates with mobile phone applications in the marketing, financial, and ticketing industries; and m2Workflow, a customer relations management solution on mobile phones for service industries. In addition, it develops and licenses portal software products that enable customers to operate their own online social networking portal without requiring any technical programming or Website design skills, as well as provides custom software programming services to customers who license its products. Further, the company specializes in data and voice telecommunications technologies. Jinzisheng Holding Group was founded in 2004 and is based in Toronto, Canada.
Full JGHG Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.